<DOC>
	<DOCNO>NCT01332396</DOCNO>
	<brief_summary>Data safety efficacy TYKERB shall collect patient order grasp actual condition post-marketing use ass background information patient .</brief_summary>
	<brief_title>Drug Use Investigation TYKERB Tablet ( All Case Investigation )</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Patients HER2 overexpressing inoperable recurrent breast cancer Patients hypersensitivity lapatinib component Pregnant woman woman suspect pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>